PAVmed Q3 revenue $0.8M, net loss $0.16/share; Lucid revenue surges 392% sequentially

PAVmed Inc.

2023-Q3 EPS reported -$0.48 revenue$1,403,000

Q3 2023 revenue $0.8M; GAAP net loss $17.7M ($0.16 per share), non-GAAP adjusted loss $9.7M ($0.09).
Lucid generated $783K revenue, up 392% sequentially; EsoGuard testing volumes up 17% sequentially and 137% YoY.
Cash and equivalents $26.4M at Sept 30, down from $37.2M at June 30, reflecting ongoing cash burn.
Veris Health launching next-gen Cancer Care Platform in Q4; on track for FDA 510(k) submission next year and implantable monitor in 2024.
Lucid launched EsoGuard 2.0 with enhanced performance and lower per-sample costs; clinical utility data showed 98-100% concordance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.